Geron (GERN) EBT Margin (2010 - 2026)

Geron (GERN) posted EBT Margin of 6.88% for Q1 2026, down 131.56% sequentially from 21.81% in Q4 2025, and up 4299.0% YoY from 0.16% in Q1 2025.

Geron (GERN) EBT Margin (2010 - 2026) Analysis & Trends

Geron has reported EBT Margin for 17 years, with the latest figure at 6.88% in Q1 2026.

Quarterly EBT Margin rose 4299.0% year-over-year to 6.88% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 416.22% (down 7185.0% YoY) and the FY2025 annual result came in at 12863.55%, up 10417813.0% from the prior year.
EBT Margin retreated to 6.88% in Q1 2026 per GERN's latest filing, from 21.81% in the prior quarter.
Over five years, EBT Margin peaked at 23700.47% in Q4 2023 and troughed at 181719.05% in Q1 2023.
A 5-year average of 29382.91% and a median of 7632.65% in 2024 frame the typical range for EBT Margin.
The sharpest annual moves came in 2023 and 2024: EBT Margin tumbled 15676539 bps in 2023, then jumped 16351905 bps in 2024.
Over 5 years, EBT Margin stood at 39799.03% in 2022, then soared by 160 bps to 23700.47% in 2023, then tumbled by 100 bps to 81.49% in 2024, then tumbled by 73 bps to 21.81% in 2025, then slumped by 132 bps to 6.88% in 2026.
According to Business Quant data, EBT Margin over the past three periods registered 6.88%, 21.81%, and 38.68% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	139.47 Bn	131.61 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	86.36 Bn	78.37 Bn	3.93 Bn	35.61%
3	Argenx Se	65.16 Bn	59.98 Bn	1.37 Bn	35.71%
4	Moderna	58.99 Bn	53.85 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	42.08 Bn	36.98 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	31.74 Bn	28.43 Bn	992.69 Mn	13.77%
7	BioNTech SE	28.01 Bn	9.61 Bn	668.28 Mn	-25.06%
8	Insmed	27.50 Bn	26.34 Bn	358.27 Mn	-2.67%
9	Royalty Pharma	27.28 Bn	26.45 Bn	-	12.09%
10	Geron	1.03 Mn	-299.82 Mn	-	-29.00%

Download Data